JP2005514071A - 内皮細胞との前培養による遺伝子導入効率の上昇 - Google Patents
内皮細胞との前培養による遺伝子導入効率の上昇 Download PDFInfo
- Publication number
- JP2005514071A JP2005514071A JP2003560222A JP2003560222A JP2005514071A JP 2005514071 A JP2005514071 A JP 2005514071A JP 2003560222 A JP2003560222 A JP 2003560222A JP 2003560222 A JP2003560222 A JP 2003560222A JP 2005514071 A JP2005514071 A JP 2005514071A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- positive
- cell
- negative
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002889 endothelial cell Anatomy 0.000 title claims abstract description 77
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 22
- 238000012546 transfer Methods 0.000 title claims abstract description 20
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 141
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 141
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims abstract description 93
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims abstract description 93
- 210000004556 brain Anatomy 0.000 claims abstract description 69
- 210000000130 stem cell Anatomy 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000013598 vector Substances 0.000 claims abstract description 17
- 102000004127 Cytokines Human genes 0.000 claims abstract description 14
- 108090000695 Cytokines Proteins 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 9
- 208000032839 leukemia Diseases 0.000 claims abstract description 7
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 6
- 210000004925 microvascular endothelial cell Anatomy 0.000 claims abstract description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 204
- 210000001185 bone marrow Anatomy 0.000 claims description 34
- 238000010361 transduction Methods 0.000 claims description 33
- 230000026683 transduction Effects 0.000 claims description 33
- 230000001177 retroviral effect Effects 0.000 claims description 28
- 239000002609 medium Substances 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 11
- 102000000646 Interleukin-3 Human genes 0.000 claims description 10
- 108010002386 Interleukin-3 Proteins 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 229940076264 interleukin-3 Drugs 0.000 claims description 10
- 229940100601 interleukin-6 Drugs 0.000 claims description 10
- 108700014844 flt3 ligand Proteins 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 31
- 238000001415 gene therapy Methods 0.000 abstract description 5
- 102000029749 Microtubule Human genes 0.000 description 64
- 108091022875 Microtubule Proteins 0.000 description 64
- 210000004688 microtubule Anatomy 0.000 description 64
- 238000003501 co-culture Methods 0.000 description 39
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 22
- 238000009630 liquid culture Methods 0.000 description 22
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 16
- 241001430294 unidentified retrovirus Species 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000004114 suspension culture Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000006194 liquid suspension Substances 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 230000001332 colony forming effect Effects 0.000 description 9
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000013553 cell monolayer Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 230000018199 S phase Effects 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- -1 stem cell factor Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241001440741 CHER virus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 101150039027 ampH gene Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34186801P | 2001-12-21 | 2001-12-21 | |
| PCT/US2002/040719 WO2003060138A1 (en) | 2001-12-21 | 2002-12-20 | In increasing gene transfer efficiency by pre-incubation with endothelial cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514071A true JP2005514071A (ja) | 2005-05-19 |
| JP2005514071A5 JP2005514071A5 (https=) | 2006-04-13 |
Family
ID=23339354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003560222A Pending JP2005514071A (ja) | 2001-12-21 | 2002-12-20 | 内皮細胞との前培養による遺伝子導入効率の上昇 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1463821A4 (https=) |
| JP (1) | JP2005514071A (https=) |
| AU (1) | AU2002360674A1 (https=) |
| WO (1) | WO2003060138A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016539659A (ja) * | 2013-10-24 | 2016-12-22 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006014814D1 (de) * | 2005-04-21 | 2010-07-22 | Massachusetts Inst Technology | Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe |
| CN101735979B (zh) * | 2009-12-31 | 2014-04-30 | 浙江中赢控股集团有限公司 | 体外扩增造血干细胞和前体细胞的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811297A (en) * | 1996-03-07 | 1998-09-22 | Amba Biosciences, Llc | Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages |
| JP2004523202A (ja) * | 2000-06-09 | 2004-08-05 | ウニベルジテートスクリーニクム シャリテー メディツィニーシェ ファクルテート デル フンボルト−ウニベルジテート ツー ベルリン，アカデミッシェ ファーバルツング−フォルシュン | 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用 |
| WO2002078449A2 (en) * | 2001-04-02 | 2002-10-10 | Advanced Cell Technology, Inc. | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells |
-
2002
- 2002-12-20 AU AU2002360674A patent/AU2002360674A1/en not_active Abandoned
- 2002-12-20 EP EP02795952A patent/EP1463821A4/en not_active Withdrawn
- 2002-12-20 WO PCT/US2002/040719 patent/WO2003060138A1/en not_active Ceased
- 2002-12-20 JP JP2003560222A patent/JP2005514071A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016539659A (ja) * | 2013-10-24 | 2016-12-22 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
| JP2020124200A (ja) * | 2013-10-24 | 2020-08-20 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1463821A4 (en) | 2006-05-31 |
| WO2003060138A1 (en) | 2003-07-24 |
| EP1463821A1 (en) | 2004-10-06 |
| AU2002360674A1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6645489B2 (en) | Methods and devices for the long-term culture of hematopoietic progenitor cells | |
| US6225119B1 (en) | Production of megakaryocytes by the use of human mesenchymal stem cells | |
| CN106062201B (zh) | 方法 | |
| AU717783B2 (en) | Methods for use of Mpl ligands with primitive human stem cells | |
| JP2002527101A (ja) | ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進 | |
| Guven et al. | Efficient gene transfer into primary human natural killer cells by retroviral transduction | |
| JPWO2003038076A1 (ja) | 不死化間葉系細胞及びその利用 | |
| US5837507A (en) | Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods | |
| Hennemann et al. | High-efficiency retroviral transduction of mammalian cells on positively charged surfaces | |
| Ng et al. | Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38–haematopoietic stem cells | |
| JP2005514071A (ja) | 内皮細胞との前培養による遺伝子導入効率の上昇 | |
| US20020086383A1 (en) | Hematopoietic stem cell expansion enhancing factor and method of use | |
| Cohen-Haguenauer et al. | Efficient transduction of hemopoietic CD34+ progenitors of human origin using an original retroviral vector derived from Fr-MuLV-FB29: in vitro assessment | |
| Sellers et al. | The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction | |
| Chute et al. | Preincubation with endothelial cell monolayers increases gene transfer efficiency into human bone marrow CD34+ CD38-progenitor cells | |
| EP1551970A2 (en) | Stem cell expansion factor blocking a gene limiting hox-induced expansion and method using such factor | |
| KR20260052087A (ko) | 시험관내 대규모 기능성 혈소판 생성을 위한 성체 인간 조혈 줄기 세포 및 전구 세포로부터 불멸화 전구 거핵구를 제조하는 방법 | |
| US20100209396A1 (en) | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells | |
| Berger et al. | Efficient retrovirus-mediated transduction of primitive human peripheral blood progenitor cells in stroma-free suspension culture | |
| WO2025031669A1 (en) | Method of producing immortalized progenitor megakaryocytes from adult human hematopoietic stem and progenitor cells for in vitro large-scale functional platelet generation | |
| Zhang et al. | Mesenchymal stem cells | |
| Garrett et al. | Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296 | |
| Bertolini et al. | Gene transfer-mediated generation of drug-resistant hemopoiesis | |
| Chen | Selective expansion of GP 91phox gene-modified murine haematopoeitic stem cells | |
| Sharma | The role of the hiwi gene in human hematopoiesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090106 |